COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review
When the Coronavirus Disease 2019 (COVID-19) appeared, it was unknown what impact it would have on the condition of patients with autoimmunological disorders. Attention was focused on the course of infection in patients suffering from multiple sclerosis (MS), specially treated with disease-modifying...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/11/9231 |
| _version_ | 1797597469367861248 |
|---|---|
| author | Marcin Bazylewicz Monika Gudowska-Sawczuk Barbara Mroczko Jan Kochanowicz Alina Kułakowska |
| author_facet | Marcin Bazylewicz Monika Gudowska-Sawczuk Barbara Mroczko Jan Kochanowicz Alina Kułakowska |
| author_sort | Marcin Bazylewicz |
| collection | DOAJ |
| description | When the Coronavirus Disease 2019 (COVID-19) appeared, it was unknown what impact it would have on the condition of patients with autoimmunological disorders. Attention was focused on the course of infection in patients suffering from multiple sclerosis (MS), specially treated with disease-modifying therapies (DMTs) or glucocorticoids. The impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the occurrence of MS relapses or pseudo-relapses was important. This review focuses on the risk, symptoms, course, and mortality of COVID-19 as well as immune response to vaccinations against COVID-19 in patients with MS (PwMS). We searched the PubMed database according to specific criteria. PwMS have the risk of infection, hospitalization, symptoms, and mortality due to COVID-19, mostly similar to the general population. The presence of comorbidities, male sex, a higher degree of disability, and older age increase the frequency and severity of the COVID-19 course in PwMS. For example, it was reported that anti-CD20 therapy is probably associated with an increased risk of severe COVID-19 outcomes. After SARS-CoV-2 infection or vaccination, MS patients acquire humoral and cellular immunity, but the degree of immune response depends on applied DMTs. Additional studies are necessary to corroborate these findings. However, indisputably, some PwMS need special attention within the context of COVID-19. |
| first_indexed | 2024-03-11T03:06:30Z |
| format | Article |
| id | doaj.art-557ea3e51e1f49639637e25e93c3773e |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T03:06:30Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-557ea3e51e1f49639637e25e93c3773e2023-11-18T07:56:13ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-012411923110.3390/ijms24119231COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic ReviewMarcin Bazylewicz0Monika Gudowska-Sawczuk1Barbara Mroczko2Jan Kochanowicz3Alina Kułakowska4Department of Neurology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Bialystok, PolandDepartment of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, PolandDepartment of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, PolandDepartment of Neurology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Bialystok, PolandDepartment of Neurology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Bialystok, PolandWhen the Coronavirus Disease 2019 (COVID-19) appeared, it was unknown what impact it would have on the condition of patients with autoimmunological disorders. Attention was focused on the course of infection in patients suffering from multiple sclerosis (MS), specially treated with disease-modifying therapies (DMTs) or glucocorticoids. The impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection on the occurrence of MS relapses or pseudo-relapses was important. This review focuses on the risk, symptoms, course, and mortality of COVID-19 as well as immune response to vaccinations against COVID-19 in patients with MS (PwMS). We searched the PubMed database according to specific criteria. PwMS have the risk of infection, hospitalization, symptoms, and mortality due to COVID-19, mostly similar to the general population. The presence of comorbidities, male sex, a higher degree of disability, and older age increase the frequency and severity of the COVID-19 course in PwMS. For example, it was reported that anti-CD20 therapy is probably associated with an increased risk of severe COVID-19 outcomes. After SARS-CoV-2 infection or vaccination, MS patients acquire humoral and cellular immunity, but the degree of immune response depends on applied DMTs. Additional studies are necessary to corroborate these findings. However, indisputably, some PwMS need special attention within the context of COVID-19.https://www.mdpi.com/1422-0067/24/11/9231COVID-19SARS-CoV-2antibodiesmultiple sclerosisvaccinationimmune response |
| spellingShingle | Marcin Bazylewicz Monika Gudowska-Sawczuk Barbara Mroczko Jan Kochanowicz Alina Kułakowska COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review International Journal of Molecular Sciences COVID-19 SARS-CoV-2 antibodies multiple sclerosis vaccination immune response |
| title | COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review |
| title_full | COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review |
| title_fullStr | COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review |
| title_full_unstemmed | COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review |
| title_short | COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review |
| title_sort | covid 19 the course vaccination and immune response in people with multiple sclerosis systematic review |
| topic | COVID-19 SARS-CoV-2 antibodies multiple sclerosis vaccination immune response |
| url | https://www.mdpi.com/1422-0067/24/11/9231 |
| work_keys_str_mv | AT marcinbazylewicz covid19thecoursevaccinationandimmuneresponseinpeoplewithmultiplesclerosissystematicreview AT monikagudowskasawczuk covid19thecoursevaccinationandimmuneresponseinpeoplewithmultiplesclerosissystematicreview AT barbaramroczko covid19thecoursevaccinationandimmuneresponseinpeoplewithmultiplesclerosissystematicreview AT jankochanowicz covid19thecoursevaccinationandimmuneresponseinpeoplewithmultiplesclerosissystematicreview AT alinakułakowska covid19thecoursevaccinationandimmuneresponseinpeoplewithmultiplesclerosissystematicreview |